Protocol Ledger

NCT07165028 · Phase III · RECRUITING

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Interventional Phase III clinical trial protocol NCT07165028 sponsored by Eli Lilly and Company in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-15 Enrollment: 4,500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07165028
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07165028
Protocol FieldVerified Registry Value
NCT IdentifierNCT07165028
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment4,500 participants (ESTIMATED)
Registered Start Date2025-10-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07165028
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI